Alcon
Native name | Alcon AG |
|---|---|
| Company type | Public |
| Industry | Ophthalmology |
| Founded | 1945 in Fort Worth, Texas, US |
| Headquarters | , Switzerland |
Key people | David Endicott (CEO) |
| Products | |
| Revenue | US$9.91 billion (2024) |
| US$1.41 billion (2024) | |
| US$1.02 billion (2024) | |
| Total assets | US$30.3 billion (2024) |
| Total equity | US$21.6 billion (2024) |
Number of employees | 25,599 (FTE, 2024) |
| Website | alcon |
| Footnotes / references | |
Alcon Inc. (German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.